Stason Pharmaceuticals, Inc.
Stason Pharmaceuticals, Inc. appears in FDA public data with 2 recalls, 0 510(k) clearances, 11 FDA inspections, and 1 compliance action on record. Its most recent recall (D-0367-2024, Class III) was initiated on February 9, 2024.
Summary
- Total Recalls
- 2
- 510(k) Clearances
- 0
- Inspections
- 11
- Compliance Actions
- 1
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0367-2024 | Class III | Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b) 250-count | February 9, 2024 |
| D-1479-2016 | Class III | Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, | August 23, 2016 |